Navigation Links
DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy

zation at chromatin level.

It is known that the kinases ATM/ATR and DNA-PK are involved in the general cellular response to DNA damage by signaling proteins that control cell cycle, apoptosis and DNA repair. In particular, ATM and DNA-PK both phosphorylate the H2AX, an isoform of the histone H2A, after exposure to ionizing radiation. The appearance of the phosphorylated H2AX, called gamma-H2AX, in cell nuclei is an indicator of DSB repair foci.

Our data provides evidence that Dbait specifically activates DNA-PK but not ATM kinase activity, as the phosphorylation of H2AX is in a DNA-PK dependent manner. Dbait-induced H2AX phosphorylation persists more than 6 days as compared to 1 day for irradiation. Cell imaging shows that the global distribution of gamma-H2AX in the nucleus of the cells transfected by Dbait was radically different of the gamma-H2AX foci organization observed when H2AX phosphorylation was triggered by irradiation alone. This indicates that DSB repair system is dramatically disorganized in Dbait transfected cells, and points out a new mechanism of action.

In addition, the amount of gamma-H2AX is proportional to that of Dbait in cultured cells and in the cells from tumor samples. gamma-H2AX appears to be a specific biomarker of Dbait in cells. It can be easily used to monitor the bioactivity of Dbait molecules in further preclinical and clinical development.

M. Dutreix who conducted this study said "this additional mechanism of antitumoral action of Dbait molecules confirms that the use of Dbait which baits, hijacks the enzyme complexes that repair DSBs and disorganizes DSB repair system, is a novel and attractive pathway-targeting approach in molecular cancer therapy".

J.S. Sun, CEO of DNA Therapeutics comments "The elucidation of Dbait's mechanisms of action and the identification of gamma-H2AX as a specific biomarker of Dbait activity are important milestones of DNA Therapeutics' development". He adds "DNA Therape
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... 48-week investigational regimen yielded nearly double SVR rate ... protease inhibitor SCH 900518 presented at EASL annual ... SGP ) today reported that final ... its investigational oral hepatitis C protease inhibitor, in ...
... Potential of Fully Human Anti-PS Antibodies and ... Equivalent to the Human Antibody Inhibited Tumor ... More than 90%-DENVER and TUSTIN, Calif., April ... PPHM), a clinical stage biopharmaceutical company ...
Cached Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
(Date:5/22/2013)... genomic health disparities from the University of Miami Miller ... Medicine have teamed up to hold the second annual ... in Genomic Medicine." The theme of this year,s ... government to reduce these disparities. , Despite steady improvement ... within underserved groups continue to be more vulnerable to ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2
... (HealthDay News) -- Teens undergoing treatment for alcohol or ... by groups such as Alcoholics Anonymous (AA) and Narcotics ... widely available, little research has looked at how effective ... 127 teen substance abuse-treatment outpatients (95 males, 32 females, ...
... April 16 (HealthDay News) -- Surgery for non-melanoma skin cancer ... mainly due to the increased use of a specific surgical ... in the outer layer of the skin or in skin ... according to the U.S. National Cancer Institute. More than ...
... Reinberg HealthDay Reporter , MONDAY, April 16 (HealthDay ... in the brains of people with multiple sclerosis (MS), researchers ... ONO-4641, "actually caused a reduction in relapses, which is somewhat ... said lead researcher Dr. Timothy Vollmer, a professor of neurology ...
... HealthDay Reporter , MONDAY, April 16 (HealthDay News) -- In a ... participated in the "choking game," in which blood and oxygen to ... produce a euphoric "high." What,s more, the researchers found that ... and many practiced other risky behaviors. "If kids do participate, ...
... Early symptoms of major mental illness can be ... be missed, or even ignored due to conventional wisdom ... deterioration and prolonged patterns of abnormality before diagnosing and ... waiting until someone is so ill that the psychological ...
... thought to play a crucial role in regulating cell proliferation. ... and interact with one another in intact animals., This study ... functional placenta and for balancing the effect of an E2F ... genes in a family of regulatory genes are vital for ...
Cached Medicine News:Health News:12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse 2Health News:Surgery Rates Rising for Non-Melanoma Skin Cancer: Study 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 3Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 2Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 3Health News:First contact: Early intervention key in diagnosis and treatment of serious mental illness 2Health News:2 repressor genes identified as essential for placental development 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: